Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (231)	6/23/2004 4:47:23 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

>>Huh?>> Early, generally small, shot-gun type of trials to find out if the drug might give some benefits in a wide variety of different tumors. Gives the impression that the investigators are not really sure about what they should be looking for. Trisenox may well bring benefits in solid cancers, but we will have to wait for conclusion of these trials before we know more. The drug is interesting as both its side-effect profile and mode of action might differ from the "nomal" chemotherapies. It might very well find a niche in various types of drug combinations. Erik

To: tuck who wrote (231)	7/14/2004 4:41:17 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

>>Huh?>> From the prospectus CTIC filed for their secondary share issue it is pretty clear that the Trisenox development focus for the time being is restricted to blood-borne cancers. We have recently refocused our TRISENOX development efforts to approximately 40 clinical and investigator-sponsored trials, with an emphasis on blood-related cancers, including front-line APL and multiple myeloma. and We believe further investments in registration-directed trials for various blood-related cancers including front-line APL, multiple myeloma and MDS could accelerate TRISENOX sales growth and increase the drug’s commercial potential. Erik sec.gov